Clinical Trial

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Name: ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — clinical trial record (NCT07011706)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

Protocol Amendment History 15 amendments

This ClinicalTrials.gov record has been amended 15 times since 2025-06-05; most recent amendment 2026-03-24.

Status change: Recruiting → Active, Not Recruiting 2026-03-24

Trial Details

NCT Number	NCT07011706
Lead Sponsor	Aclaris Therapeutics, Inc.
Conditions	Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Enrollment	110 participants
Start Date	2025-05-30
Primary Completion	2026-08 (estimated)
Study Completion	2026-10 (estimated)
Updated on ClinicalTrials.gov	2026-03-25